Research
Hormonal
Statin use is associated with a reduced incidence of hepatocellular carcinoma in patients with NAFLD.
If you have fatty liver disease, ask your doctor if a statin is appropriate for you. Studies suggest that statins may lower your risk of liver cancer in addition to helping with cholesterol and cardiovascular health.
GoodSupportsMEDIUM confidence
a systematic meta-analysis of 26 randomized controlled trials, including almost 1.5 million patients and 4,298 cases of HCC, showed that the use of statins was associated with a 37% reduction in HCC incidence after adjusting for potential confounders
Why this rating
Based on a large systematic meta-analysis of RCTs.
Source
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Andrea Marengo et al. · Annual Review of Medicine · 2015
DOI 10.1146/annurev-med-090514-013832
narrative_reviewCited 790×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity and metabolic syndrome significantly increase the risk of hepatocellular carcinoma (HCC), with risk escalating as BMI increases and being further amplified by the presence of type 2 diabetes.Strong
- Hepatocellular carcinoma can develop in patients with nonalcoholic fatty liver disease (NAFLD) even in the absence of cirrhosis, often presenting with larger tumors and poorer prognosis due to lack of surveillance.Good
- Metformin use is associated with a reduced incidence of hepatocellular carcinoma in patients with type 2 diabetes, whereas sulfonylurea or insulin use may increase risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →